Navigation Links
Tigris Pharmaceuticals Appoints Neil Flanzraich to Executive Chairman of the Board

BONITA SPRINGS, Fla., Sept. 28 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held drug development company, is pleased to announce the appointment of Mr. Neil Flanzraich as Executive Chairman of the Board of Directors.

"The appointment of Mr. Flanzraich is a very important milestone for Tigris Pharmaceuticals' future," said Edmundo Muniz, MD, PhD, President and CEO of Tigris, adding, "Neil brings to Tigris extraordinary ability and pharmaceutical industry experience and a remarkable track record of success. We are extremely pleased to welcome him to our company."

Mr. Flanzraich also serves as Chairman of ParinGenix, Inc., another privately owned biotechnology company.  He is also the founder and a principal of a venture capital firm, Leviathan Biopharma Group, LLC.  

For over seven years, prior to its sale in 2006, Mr. Flanzraich served as Vice Chairman and President of IVAX Corporation, an international pharmaceutical company acquired by TEVA Pharmaceutical Industries, Ltd. Prior to his tenure at IVAX, Mr. Flanzraich served as Chairman of the Life Sciences Legal Practice Group of Heller Ehrman LLP, a law firm, and for thirteen years, he worked at Syntex Corporation, an international pharmaceutical company, where he was Senior Vice President and member of the Corporate Operating Committee.

"I am delighted to become Tigris Pharmaceuticals' Executive Chairman," said Mr. Flanzraich.  "I am joining a leadership team with deep expertise and an impressive record of accomplishment.  Our combined capabilities, shared values and focus and the company's exciting pipeline will make Tigris an extraordinarily successful enterprise."

Mr. Flanzraich serves as a director of Equity One, Inc., a real estate company, Continucare Corporation, a mixed model provider of primary care physician services, Chipotle Mexican Grill, a developer and operator of fast-casual, fresh Mexican food restaurants in the United States, and Canada, and England and Bellus Health, a biotechnology company focused on neurology products.  He also serves as a director of privately owned, Outcomes Health Information Solutions, LLC, a provider of healthcare data retrieval, analytic and management services.

Mr. Flanzraich graduated from Harvard College (magna cum laude, Phi Beta Kappa) and from Harvard Law School (magna cum laude).  

About Tigris Pharmaceuticals, Inc.

Tigris Pharmaceuticals, Inc. is a privately held biopharmaceutical company that develops therapeutic technologies to treat oncology and other human diseases.  Tigris is currently initiating a Phase II trial for AFP-464, a novel anticancer agent in patients with breast cancer and is also conducting a multi-center Phase I dose escalation study for GGTI-2418, another first-in-class agent, at Abramson Cancer Center at The University of Pennsylvania and Indiana University Melvin and Bren Simon Cancer Center.  

With a management team that has a proven track record in guiding molecules from the early stages of clinical development to successful worldwide approvals, we offer large pharmaceutical drug development expertise in conjunction with the agility and speed of a small organization.Contact:  For Tigris PharmaceuticalsElaine FloydTigris Pharmaceuticals, Inc.(239) 444-5400info@tigrispharma.comThis news release contains forward-looking statements.  Such statements are valid only as of today, and Tigris disclaims any obligation to update this information.  These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.  These statements are based on the company's current beliefs and expectations as to such future outcomes.  Drug development involves a high degree of risk.  Factors that might cause such a material difference include, among others uncertainties related to Tigris' ability to attract and retain partners for its technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, its pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates from other pharmaceutical companies, product pricing and third party reimbursement.


SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
2. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
3. Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion
4. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
5. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
6. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
7. Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.
8. Lotus Pharmaceuticals Announces Two Senior Management Appointments
9. NewBridge Pharmaceuticals Signs Agreement for Abstral™ for the Middle East and Africa
10. Endo Pharmaceuticals Receives FDA Priority Review for New Formulation of Long-Acting Oxymorphone Designed to be Crush Resistant
11. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
Post Your Comments:
(Date:11/26/2015)... 26, 2015 3D bioprinting market ... to a new report by Grand View Research Inc. Rising ... which demands kidney transplantation is expected to boost the market ... for organ transplantation. --> 3D bioprinting market ... to a new report by Grand View Research Inc. Rising ...
(Date:11/26/2015)... November 26, 2015 ... universitetssjukhus ser potential att använda SyMRI för ... för patienter med multipel skleros (MS) ... med SyntheticMR AB för att kunna använda ... sjukhuset. Med SyMRI kan man generera flera ...
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Italian ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... November 28, 2015 , ... StatRad , ... added Chris Hafey and Claude Hooton to its board of directors. The announcement ... America (RSNA) 2015 Annual Meeting and continues to strategically transform its focus from ...
(Date:11/28/2015)... ... November 28, 2015 , ... Beginning November 30th at 6:00 a.m. EST until 11:59 p.m. EST, ... With possible savings of up to 20% off orders $80 or more to free gifts ... every few hours. , As a competitive e-commerce website for skin care and cosmetic needs, ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published November ... meeting in Washington D.C. revolved around the fact that proper dental care, both at-home ... stressed the link between periodontal disease (more commonly referred to as gum disease) and ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... affecting the health care in America. As people age, more care is needed, ... costs are rising, and medical professionals are being overworked. The forgotten part of ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When ... said an inventor from Hillside, N.J. "Many people catch diseases simply from sitting ... individuals will always be protected from germs." , He developed the patent-pending QUDRATECS ...
Breaking Medicine News(10 mins):